The global portal hypertension management market is set to experience robust growth over the next decade, according to recent market analysis. The market, valued at USD 3.05 billion in 2023, is expected to expand at a compound annual growth rate (CAGR) of 5% from 2023 to 2033, reaching an estimated USD 4.97 billion by the end of the forecast period.
Generic drugs currently dominate the portal hypertension management market, with key treatments including vasopressin and its analogs, beta-blockers, and somatostatin and its analogs. The increasing demand for these medications highlights promising prospects for continued advancements and research in treatment options. Additionally, duplex Doppler ultrasonography, the leading imaging method for diagnosing portal hypertension, has seen a significant rise in demand, further driving market growth.
Our Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16585
Cirrhosis, a primary cause of portal hypertension characterized by the replacement of healthy liver cells with scar tissue, is a major factor contributing to market expansion. The condition is more prevalent in men than in women, according to the National Institute of Diabetes and Digestive and Kidney Diseases. The growing number of individuals with cirrhosis, particularly among the aging population, is expected to fuel market growth over the coming years.
Regional Insights:
North America currently holds the largest market share, driven by high technological advancements in healthcare services and increasing demand for beta-blockers. The region’s leadership is expected to continue due to the rising incidence and prevalence of rare diseases and improvements in in-patient care.
Asia-Pacific is the second-largest market, bolstered by its growing elderly population and high prognosis rate. The region’s market revenue is expected to rise significantly, supported by these demographic trends.
The liver transplantation segment is experiencing substantial growth due to the global increase in demand for transplantable organs. In the United States alone, approximately 122,913 diagnoses were awaiting organ transplants in 2019, according to the U.S. Department of Health and Human Services. This growing demand for sophisticated transplantation products is propelling the segment’s expansion.
Key Takeaways from the Market Study:
- From 2018 to 2022, sales witnessed major growth, registering a CAGR of 3%
- The global portal hypertension management market is predicted to garner a market value of USD 97 Billion.
- Portal hypertension management market in North America is expected to grow at a CAGR of 4%
- Endoscopic therapy to be most preferred, expected to grow at a CAGR of 7%.
- The Asia Pacific market is expected to account for 40% of the market share.
“The therapies under advancement are focused on novel approaches to treating/improving disease signs. Companies involved are working on developing Portal Hypertension therapies. The launch of new treatments will have a significant impact on the portal hypertension management market.” says FMI’s analyst.
Customization with Our Report: https://www.futuremarketinsights.com/customization-available/rep-gb-16585
Competitive Landscape:
Key players in the Portal Hypertension Management market are Ono Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd. Some recent developments by manufacturers are below
- In August 2022, ONO received approval in Japan for Onoact® for Intravenous Infusion 50mg/150mg (“Onoact”), a short-acting selective 1 blocker.
- In March 2021, Gilead Sciences announced that it would expand its collaboration with Novo Nordisk and gain knowledge of the prospects for composite strategies in helping patients with cirrhosis caused by NASH, contributing to the portal hypertension management market.
Key Segments Profiled in the Portal Hypertension Management Industry Survey:
By Treatment:
- Liver Transplantation
- Endoscopic Therapy
- Banding
- Balloon Tamponade
- Shunting Procedures
- Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt
- Surgical Shun
- Drug Class
- Octapeptides
- Cofactors
- PDE5 Inhibitor
- Beta Blockers
By End Users:
- Hospitals
- Specialty Clinic
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Get Complete Full Report: https://www.futuremarketinsights.com/checkout/16585
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube